东方生物
(688298)
| 流通市值：52.94亿 | | | 总市值：52.94亿 |
| 流通股本：2.02亿 | | | 总股本：2.02亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 191,951,815.38 | 827,916,211.63 | 657,613,863.02 | 418,235,233.09 |
| 营业收入 | 191,951,815.38 | 827,916,211.63 | 657,613,863.02 | 418,235,233.09 |
| 二、营业总成本 | 308,694,803.36 | 1,250,501,323.18 | 1,015,757,409.45 | 624,188,833.28 |
| 营业成本 | 139,434,234.62 | 565,129,983.54 | 429,479,876.84 | 269,301,346.85 |
| 税金及附加 | 2,919,601.58 | 15,208,598.12 | 5,126,317.49 | 3,088,599 |
| 销售费用 | 44,144,356.3 | 188,889,275.73 | 115,645,578.78 | 72,500,539.19 |
| 管理费用 | 89,889,197.4 | 408,116,261.09 | 301,544,840.3 | 204,636,205.23 |
| 研发费用 | 58,725,780.47 | 290,492,717.57 | 209,881,229.54 | 146,302,173.83 |
| 财务费用 | -26,418,367.01 | -217,335,512.87 | -45,920,433.5 | -71,640,030.82 |
| 其中:利息费用 | 3,822,682.99 | 19,248,751.64 | 14,332,103.62 | 10,259,896.71 |
| 其中:利息收入 | 16,762,037.53 | 193,000,771.63 | 83,735,447.92 | 71,646,394.71 |
| 加:公允价值变动收益 | -1,556,541.35 | 10,654,769.31 | 15,159,826.64 | 15,460,200.59 |
| 加:投资收益 | 2,459,380.31 | 29,776,712.67 | 70,757,363.61 | 42,503,594.04 |
| 资产处置收益 | -14,378.51 | 987,647.61 | 904,167.89 | -55,152.15 |
| 资产减值损失(新) | -4,474,395.22 | -175,703,291.62 | -16,640,365.02 | -9,024,879.15 |
| 信用减值损失(新) | -3,617,319.06 | -29,130,420.16 | 419,628.48 | -6,479,045.03 |
| 其他收益 | 459,866.43 | 7,169,080.66 | 4,996,672.21 | 3,764,476.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -123,486,375.38 | -578,830,613.08 | -282,546,252.62 | -159,784,405.43 |
| 加:营业外收入 | 32,040.48 | 8,892,861.64 | 6,887,356.75 | 3,667,750.26 |
| 减:营业外支出 | 120,292.89 | 15,373,073.78 | 2,028,129.64 | 1,333,238.16 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -123,574,627.79 | -585,310,825.22 | -277,687,025.51 | -157,449,893.33 |
| 减:所得税费用 | -2,804,504.85 | -16,488,362.73 | -3,459,475.91 | 2,594,118.89 |
| 六、净利润 | -120,770,122.94 | -568,822,462.49 | -274,227,549.6 | -160,044,012.22 |
| 持续经营净利润 | -120,770,122.94 | -568,822,462.49 | -274,227,549.6 | -160,044,012.22 |
| 归属于母公司股东的净利润 | -115,452,483.95 | -529,022,760.88 | -262,156,256.43 | -151,607,488.56 |
| 少数股东损益 | -5,317,638.99 | -39,799,701.61 | -12,071,293.17 | -8,436,523.66 |
| (一)基本每股收益 | -0.57 | -2.69 | -1.32 | -0.76 |
| (二)稀释每股收益 | -0.57 | -2.69 | -1.32 | -0.76 |
| 八、其他综合收益 | -7,821,204.5 | 12,528,352.12 | -17,554,233.08 | 2,568,899.2 |
| 归属于母公司股东的其他综合收益 | -7,821,204.5 | 12,528,352.12 | -17,554,233.08 | 2,568,899.2 |
| 九、综合收益总额 | -128,591,327.44 | -556,294,110.37 | -291,781,782.68 | -157,475,113.02 |
| 归属于母公司股东的综合收益总额 | -123,273,688.45 | -516,494,408.76 | -279,710,489.51 | -149,038,589.36 |
| 归属于少数股东的综合收益总额 | -5,317,638.99 | -39,799,701.61 | -12,071,293.17 | -8,436,523.66 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |